AU2016278226B2 - Compositions and methods for directing proteins to specific loci in the genome - Google Patents

Compositions and methods for directing proteins to specific loci in the genome Download PDF

Info

Publication number
AU2016278226B2
AU2016278226B2 AU2016278226A AU2016278226A AU2016278226B2 AU 2016278226 B2 AU2016278226 B2 AU 2016278226B2 AU 2016278226 A AU2016278226 A AU 2016278226A AU 2016278226 A AU2016278226 A AU 2016278226A AU 2016278226 B2 AU2016278226 B2 AU 2016278226B2
Authority
AU
Australia
Prior art keywords
disclosure
sequence
dna
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016278226A
Other languages
English (en)
Other versions
AU2016278226A1 (en
Inventor
Xianghong Li
Eric Ostertag
Tseten YESHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poseida Therapeutics Inc
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of AU2016278226A1 publication Critical patent/AU2016278226A1/en
Application granted granted Critical
Publication of AU2016278226B2 publication Critical patent/AU2016278226B2/en
Priority to AU2021250992A priority Critical patent/AU2021250992B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016278226A 2015-06-17 2016-06-16 Compositions and methods for directing proteins to specific loci in the genome Active AU2016278226B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021250992A AU2021250992B2 (en) 2015-06-17 2021-10-18 Compositions and methods for directing proteins to specific loci in the genome

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181162P 2015-06-17 2015-06-17
US62/181,162 2015-06-17
PCT/US2016/037922 WO2016205554A1 (en) 2015-06-17 2016-06-16 Compositions and methods for directing proteins to specific loci in the genome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021250992A Division AU2021250992B2 (en) 2015-06-17 2021-10-18 Compositions and methods for directing proteins to specific loci in the genome

Publications (2)

Publication Number Publication Date
AU2016278226A1 AU2016278226A1 (en) 2018-01-25
AU2016278226B2 true AU2016278226B2 (en) 2021-08-12

Family

ID=56292934

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016278226A Active AU2016278226B2 (en) 2015-06-17 2016-06-16 Compositions and methods for directing proteins to specific loci in the genome
AU2021250992A Active AU2021250992B2 (en) 2015-06-17 2021-10-18 Compositions and methods for directing proteins to specific loci in the genome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021250992A Active AU2021250992B2 (en) 2015-06-17 2021-10-18 Compositions and methods for directing proteins to specific loci in the genome

Country Status (11)

Country Link
US (2) US11473082B2 (enExample)
EP (2) EP3310909B1 (enExample)
JP (3) JP2018521689A (enExample)
KR (1) KR102637402B1 (enExample)
CN (1) CN108026519A (enExample)
AU (2) AU2016278226B2 (enExample)
CA (1) CA2989827C (enExample)
DK (1) DK3310909T3 (enExample)
ES (1) ES2886599T3 (enExample)
PT (1) PT3310909T (enExample)
WO (1) WO2016205554A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
KR102630014B1 (ko) 2014-10-01 2024-01-25 더 제너럴 하스피탈 코포레이션 뉴클레아제-유도 상동성-지정 복구의 효율 증가 방법
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
KR102588469B1 (ko) * 2016-09-30 2023-10-11 포세이다 테라퓨틱스, 인크. 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
JP7275043B2 (ja) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド 増大したｈＡＴファミリートランスポゾン媒介遺伝子導入ならびに関連する組成物、システムおよび方法
SG10202109731YA (en) 2017-03-13 2021-10-28 Poseida Therapeutics Inc Compositions and methods for selective elimination and replacement of hematopoietic stem cells
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
AU2018299995B2 (en) * 2017-07-11 2021-10-28 Sigma-Aldrich Co. Llc Using nucleosome interacting protein domains to enhance targeted genome modification
US12227742B2 (en) 2017-10-23 2025-02-18 The Broad Institute, Inc. Nucleic acid modifiers
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
WO2019126578A1 (en) * 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
CN110938658B (zh) * 2018-09-21 2023-02-07 中国科学院分子细胞科学卓越创新中心 一种抗体进化方法及其应用
WO2020077360A1 (en) 2018-10-12 2020-04-16 Poseida Therapeutics, Inc. Hematopoietic stem cell compositions, methods of making and method of use
CN113498439A (zh) 2018-12-20 2021-10-12 波赛达治疗公司 纳米转座子组合物及使用方法
WO2020160481A1 (en) * 2019-02-01 2020-08-06 The General Hospital Corporation Targetable 3'-overhang nuclease fusion proteins
US20220204569A1 (en) * 2019-04-09 2022-06-30 Japan Science And Technology Agency Nucleic acid-binding protein
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
AU2020342544A1 (en) 2019-09-05 2022-03-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2022087354A1 (en) * 2020-10-23 2022-04-28 Altius Institute For Biomedical Sciences Cell permeable proteins for genome engineering
CN112750498B (zh) * 2020-12-30 2022-06-24 同济大学 靶向逆转录引物结合位点从而抑制hiv病毒复制的方法
US20240060090A1 (en) 2021-02-23 2024-02-22 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4297728A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20240424097A1 (en) 2021-09-09 2024-12-26 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
US20250099383A1 (en) 2022-01-21 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023164573A1 (en) * 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
WO2023209649A1 (en) * 2022-04-29 2023-11-02 Seqirus, Inc. Method of dna linearization
WO2024007010A2 (en) * 2022-06-30 2024-01-04 Demeetra Agbio, Inc. Gene editing compositions and methods of use thereof
EP4605525A1 (en) 2022-10-21 2025-08-27 Keygene N.V. Rna transfection in plant cells with modified rna
CN120225666A (zh) 2022-11-21 2025-06-27 艾欧凡斯生物治疗公司 用于评估基因编辑的t细胞的增殖效力的方法
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024121354A1 (en) 2022-12-08 2024-06-13 Keygene N.V. Duplex sequencing with covalently closed dna ends
EP4651943A1 (en) 2023-01-20 2025-11-26 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
IL322198A (en) 2023-01-20 2025-09-01 Poseida Therapeutics Inc Lipidoid compounds and related compositions and uses
CN121079405A (zh) * 2023-02-21 2025-12-05 波西达治疗公司 用于基因组编辑的组合物和方法
EP4669745A1 (en) * 2023-02-21 2025-12-31 Poseida Therapeutics, Inc. COMPOSITIONS AND GENOMIC EDITING PROCESSES
WO2024209000A1 (en) 2023-04-04 2024-10-10 Keygene N.V. Linkers for duplex sequencing
AU2024271748A1 (en) 2023-05-17 2025-11-13 Poseida Therapeutics, Inc. Compositions targeting hbg1 and hbg2 and methods of use thereof
WO2025049925A2 (en) 2023-09-01 2025-03-06 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025096980A1 (en) 2023-11-02 2025-05-08 Poseida Therapeutics, Inc. Compositions targeting klkb1 and methods of use thereof
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
WO2025171237A1 (en) 2024-02-08 2025-08-14 Poseida Therapeutics, Inc. Lipidoid compounds and related compositions and uses
WO2025221789A1 (en) 2024-04-16 2025-10-23 Poseida Therapeutics, Inc. Compositions and methods for use in car/tcr cell therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089290A1 (en) * 2012-12-06 2014-06-12 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
TW261517B (enExample) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
DE19524720A1 (de) 1995-07-12 1997-01-16 Hoechst Ag Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3"
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
JP4216350B2 (ja) 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789147A (en) 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US5928914A (en) 1996-06-14 1999-07-27 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Methods and compositions for transforming cells
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
CA2246005A1 (en) 1998-10-01 2000-04-01 Hsc Research And Development Limited Partnership Hybrid genes for gene therapy in erythroid cells
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
JP2003500051A (ja) 1999-05-25 2003-01-07 パノラマ リサーチ，インコーポレイティド 相互作用活性化タンパク質
ATE353361T1 (de) 2000-04-28 2007-02-15 Sangamo Biosciences Inc Gezielten modifikation der chromatinstruktur
AU2002243645A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger proteins for dna binding and gene regulation in plants
US7700754B1 (en) * 2001-06-05 2010-04-20 Masahiro Hiraoka Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same
US20030138850A1 (en) 2001-10-18 2003-07-24 Ekkehard Mossner Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US20060252140A1 (en) 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
US7790379B2 (en) 2005-05-19 2010-09-07 Universite De Geneve Mapping of proteins along chromatin by chromatin cleavage
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
JP2007159512A (ja) 2005-12-15 2007-06-28 Institute Of Physical & Chemical Research Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法
WO2007122511A2 (en) 2006-04-21 2007-11-01 Mab-Factory Gmbh Antibody-rnase-conjugate
WO2008130629A2 (en) 2007-04-19 2008-10-30 Codon Devices, Inc. Engineered nucleases and their uses for nucleic acid assembly
AU2008302397A1 (en) 2007-09-17 2009-03-26 Affomix Corporation Increasing specificity in a scFv screen using dual bait reporters
EP2401298A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Antigen-binding constructs
CA2751000A1 (en) 2009-03-11 2010-12-23 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
EP2571512B1 (en) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
WO2012093833A2 (en) 2011-01-03 2012-07-12 Toolgen Incorporation Genome engineering via designed tal effector nucleases
CN103328507B (zh) 2011-01-06 2016-09-07 康普里斯股份有限公司 Alphabody文库及其产生方法
US9499592B2 (en) 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
JP5996630B2 (ja) 2011-04-05 2016-09-21 セレクティスＣｅｌｌｅｃｔｉｓ コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用
EP2522726A1 (en) 2011-05-12 2012-11-14 Fundació Privada Centre de Regulació Genòmica (CRG) Zinc finger nucleases for p53 editing
WO2012158986A2 (en) 2011-05-17 2012-11-22 Transposagen Biopharmaceuticals, Inc. Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms
US20140304847A1 (en) 2011-06-07 2014-10-09 Ralf Kühn Recombination efficiency by inhibition of nhej dna repair
WO2012168304A1 (en) 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Protein having nuclease activity, fusion proteins and uses thereof
UA115772C2 (uk) 2011-12-16 2017-12-26 Таргітджин Байотекнолоджиз Лтд Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені
US20130274129A1 (en) 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
MY189533A (en) * 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9181535B2 (en) * 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
EP2931898B1 (en) 2012-12-12 2016-03-09 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20150044772A1 (en) * 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
SG11201609211VA (en) 2014-03-05 2016-12-29 Nat Univ Corp Univ Kobe Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
JP2017518083A (ja) 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物
JP2017518082A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用
CN104450785A (zh) * 2014-12-08 2015-03-25 复旦大学 使用编码靶向核酸内切酶附着体载体的基因组编辑方法及试剂盒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089290A1 (en) * 2012-12-06 2014-06-12 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation

Also Published As

Publication number Publication date
WO2016205554A1 (en) 2016-12-22
JP2018521689A (ja) 2018-08-09
ES2886599T3 (es) 2021-12-20
JP7170090B2 (ja) 2022-11-11
JP2021112211A (ja) 2021-08-05
AU2016278226A1 (en) 2018-01-25
US20180187185A1 (en) 2018-07-05
EP3310909A1 (en) 2018-04-25
US11473082B2 (en) 2022-10-18
CA2989827C (en) 2024-09-10
AU2021250992A1 (en) 2021-11-11
PT3310909T (pt) 2021-09-09
CA2989827A1 (en) 2016-12-22
AU2021250992B2 (en) 2023-09-28
KR20180036696A (ko) 2018-04-09
EP3310909B1 (en) 2021-06-09
JP2021182942A (ja) 2021-12-02
KR102637402B1 (ko) 2024-02-15
CN108026519A (zh) 2018-05-11
US20230257737A1 (en) 2023-08-17
EP3929286A1 (en) 2021-12-29
HK1253508A1 (zh) 2019-06-21
DK3310909T3 (da) 2021-09-13

Similar Documents

Publication Publication Date Title
AU2021250992B2 (en) Compositions and methods for directing proteins to specific loci in the genome
KR102606929B1 (ko) 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
CN108715861B (zh) 一种碱基编辑工具及其应用
KR102516695B1 (ko) 단백질 내로의 비-천연 아미노산의 혼입
AU2018271425B2 (en) Dna-binding protein using ppr motif, and use thereof
KR20150125994A (ko) 세포 발현 시스템
KR102227657B1 (ko) in vivo에서 RNA-가이드 뉴클레아제의 활성을 고처리량 방식으로 평가하는 방법
KR102584628B1 (ko) T-세포 수용체, t-세포 항원 및 이들의 기능성 상호작용의 식별 및 특징규명을 위한 조작된 다성분 시스템
CN108753823B (zh) 利用碱基编辑技术实现基因敲除的方法及其应用
JP7684271B2 (ja) Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
AU2017352591B2 (en) A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells
CN110437334B (zh) 全人源抗金黄色葡萄球菌α-溶血素重组抗体
CN101688231B (zh) 由茶碱调控其靶特异性核糖核酸的取代活性的变构反式剪接i型核酶
CN108531458A (zh) 治疗肿瘤的基因工程自然杀伤细胞产品
CN113583096A (zh) SARS-CoV-2 Spike蛋白受体结合域二聚体及其应用
CN116887854A (zh) Omni-103 crispr核酸酶
KR20200088805A (ko) 게놈-편집 조류
KR20230142740A (ko) Omni-103 crispr 뉴클레아제
CN111727244B (zh) 循环肿瘤细胞的通用检测探针
CN113198017B (zh) 以ITGB1蛋白为靶标的抑制剂在制备抗SARS-CoV-2药物中的应用
CN110514628A (zh) 一种快速检测O-GlcNAc修饰的生物感应器/方法及应用
KR102721254B1 (ko) 형질전환시킨 중국햄스터난소 세포를 활용하여 시시엔5 단백질을 제조하는 방법
HK40038630A (en) Probe for universal detection of circulating tumor cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)